Ocular Therapeutix seeks second indication for drug-delivery eye insert
Ocular Therapeutix (NSDQ:OCUL) said yesterday that it submitted a supplement NDA to the FDA for its dexamethasone ocular insert, Dextenza. The Bedford, Mass.-based company requested that the U.S. regulatory agency expand the current indication for Dextenza to include the treatment of ocular inflammation following eye surgery. Get the full story at our sister site, Drug Delivery Business News. The post Ocular Therapeutix seeks second indication for drug-delivery eye insert appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 11, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat oculartherapeutix Source Type: news

Dextenza (Dexamethasone Ophthalmic Insert) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 14, 2018 Category: Drugs & Pharmacology Source Type: news

Daratumumab Plus Len/Dex: New Standard of Care in Myeloma? Daratumumab Plus Len/Dex: New Standard of Care in Myeloma?
Adding daratumumab to lenalidomide and dexamethasone increased progression-free survival in transplant-ineligible patients newly diagnosed with myeloma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery
BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Ocular Therapeutix™, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 3, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Steroid Insert (Dextenza) for Postop Ocular Pain FDA OKs Steroid Insert (Dextenza) for Postop Ocular Pain
Dextenza is the first FDA-approved intracanalicular insert that delivers dexamethasone to treat ocular pain following ophthalmic surgery for up to 30 days with a single insertion.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

Ocular Therapeutix wins FDA nod for drug-delivery eye insert
Ocular Therapeutix (NSDQ:OCUL) said today that the FDA approved its resubmitted application Dextenza, an ocular insert designed to release dexamethasone to relieve pain following ophthalmic surgery. The regulatory win for the Bedford, Mass.-based company comes after much back-and-forth with the FDA; the agency has twice rejected Ocular Therapeutix’s application for Dextenza. Get the full story at our sister site, Drug Delivery Business News. The post Ocular Therapeutix wins FDA nod for drug-delivery eye insert appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat oculartherapeutix Source Type: news

Early Intervention With New Drug Combo Beneficial in Myeloma?
This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Impact of Elotuzumab on Multiple Myeloma Patients
The ELOQUENT-3 trial looks at how the of addition of elotuzumab to pomalidomide and dexamethasone impacts patient outcomes in multiple myeloma.   (Source: CancerNetwork)
Source: CancerNetwork - November 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
In phase 2 trial, longer progression - free survival for elotuzumab with pomalidomide and dexamethasone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 8, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

FDA Approves Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 6, 2018 Category: Drugs & Pharmacology Source Type: news

Alimta-Related Skin Reactions with and Without Oral Steroids
This study supports the use of intravenous dexamethasone 10 mg before pemetrexed infusion in place of three days of oral dexamethasone 4 mg twice daily at UNMCCC,” the authors wrote. The post Alimta-Related Skin Reactions with and Without Oral Steroids appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - November 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA Approves Once-Weekly Carfilzomib for Myeloma
FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - October 15, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Class 2 Medicines Recall: Ozurdex 700 micrograms intravitreal implant in applicator (Dexamethasone)
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for specific batches of Ozurdex 700 micrograms intravitreal implant in applicator (Dexamethasone), (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 5, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Approval of a More Convenient Once-Weekly Kd70 Regimen Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study Application Granted Priority Review Designation Application Reviewed and Approved Under FDA's Real-Time Oncology Review and Assessment Aid... Biopharmaceuticals, Oncology, FDA Amgen, KYPROLIS, carfilzomib, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 1, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves KYPROLIS ® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Approval of a More Convenient Once-Weekly Kd70 Regimen Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study Application Granted Priority Review Designation Application Reviewed and Approved Under FDA's Real-Time Oncology Review and Assessment Aid Pilot Programs THOUSAND OAKS, Calif., Oct. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (once-weekly...
Source: Amgen News Release - October 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

EyePoint nabs CMS reimbursement for Dexycu cataract surgery drug
EyePoint Pharmaceuticals (NSDQ:EYPT) said this week that the Centers for Medicare and Medicaid Services approved transitional pass-through status and reimbursement of its dexamethasone intraocular suspension, Dexycu. The FDA-approved product is designed to treat inflammation following cataract surgery using a single, intraocular dose of long-acting dexamethasone. Get the full story at our sister site, Drug Delivery Business News. The post EyePoint nabs CMS reimbursement for Dexycu cataract surgery drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 7, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat eyepointpharmaceuticals Source Type: news

Amgen Submits Supplemental New Drug Application For KYPROLIS ® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Filing Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study THOUSAND OAKS, Calif., Aug. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (Kd) for patients with relapsed or refractory multiple myeloma. The sNDA is based on data from the Phase 3 A.R.R.O.W. trial, demonstrating KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-weekly Kd) ...
Source: Amgen News Release - August 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Medical News Today: What is dexamethasone?
Dexamethasone oral tablet is a prescription medication used to treat conditions such as inflammation, allergic reactions, ulcerative colitis, and adrenal insufficiency. It's available as a generic drug and as the brand-name drugs DexPak and Decadron. Learn about side effects, warnings, dosage, and more. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 10, 2018 Category: Consumer Health News Tags: Pharmacy / Pharmacist Source Type: news

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS ® (carfilzomib) Label
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (car...
Source: Amgen News Release - June 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

PharmaMar presents at ASCO the ADMYRE study's adjusted overall survival with plitidepsin
(Pharmamar) PharmaMar (MSE:PHM) has presented today how crossover has had an influence on the overall survival of the ADMYRE trial. The impact on overall survival of those patients that relapsed after receiving dexamethasone as a single agent and who were subsequently treated with plitidepsin in combination with dexamethasone was analyzed. Of the 84 patients treated from the comparator arm -dexamethasone as a single agent- 44 percent, 37 patients were treated with the combination with plitidepsin thereafter. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 5, 2018 Category: Cancer & Oncology Source Type: news

Once-Weekly Bests Twice-Weekly Carfilzomib in R/R Multiple Myeloma
Leah LawrenceJun 2, 2018A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS ® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen Prespecified Interim Analysis Presented Today During Oral Session at ASCO 2018 and Simultaneously Published in The Lancet Oncology THOUSAND OAKS, Calif., June 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS® (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. In the trial, KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-...
Source: Amgen News Release - June 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS ® (carfilzomib) Label
KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies THOUSAND OAKS, Calif., April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of deat...
Source: Amgen News Release - April 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Duel of the inflammatory master regulators: Insights for drug discovery
(Emory Health Sciences) Anti-inflammatory drugs such as dexamethasone can have harmful side effects on the skin, bones and metabolism. Emory structural biology research has implications for the long-standing quest to separate these drugs' benefits from their side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2018 Category: International Medicine & Public Health Source Type: news

A Novel Combination Therapy for Refractory Multiple Myeloma A Novel Combination Therapy for Refractory Multiple Myeloma
Dexamethasone can be problematic for patients with diabetes. The authors developed a novel dexamethasone-free combination regimen for multiple myeloma, which proved effective in this diabetic patient.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Is the Use of Dexamethasone Effective in Controlling Pain Associated with Symptomatic Irreversible Pulpitis? A Systematic Review
This study was registered in the PROSPERO database (CRD42017058704), and Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement recommendations were followed. MEDLINE, Scopus, ScienceDirect, Web of Science, Latin American Caribbean Health Sciences Literature, Cochrane Library, and Google Scholar databases were used in our research. No restrictions were applied to dates or language of publication. All records identified electronically were organized and evaluated by 2 independent authors, and, in case of doubt, a third author made the decision. The Cochrane Collaboration tool was used. The data were an...
Source: Dental Technology Blog - April 2, 2018 Category: Dentistry Source Type: news

pSivida buys Icon Bioscience and rebrands as EyePoint Pharmaceuticals
With the help of $61 million from EW Healthcare Partners and a third-party investor, pSivida (NSDQ:PSDV) announced today that it acquired Icon Bioscience and its FDA-approved dexamethasone intraocular suspension designed to treat postoperative inflammation. The two companies combined and plan to do business as EyePoint Pharmaceuticals. pSivida also landed a $20 million debt facility from SWK Holdings Corp., to help fund the Icon buyout and prepare for the commercial launch of Icon’s Dexycu product. Get the full story at our sister site, Drug Delivery Business News. The post pSivida buys Icon Biosc...
Source: Mass Device - March 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Mergers & Acquisitions Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat iconbioscience pSivida Corp. Source Type: news

Ixazomib Triplet Combo Effective in R/R Myeloma
The oral therapy combination of ixazomib, pomalidomide, and dexamethasone was effective and well-tolerated in patients with myeloma that had relapsed or was refractory to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

Pomalidomide/Dexamethasone Effective in R/R Myeloma With Renal Insufficiency
Nearly 80% of R/R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination. (Source: CancerNetwork)
Source: CancerNetwork - February 28, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma Source Type: news

Dexycu (Dexamethasone Intraocular Suspension 9%, for Intraocular Administration) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

Icon Bioscience Receives FDA Approval for Dexycu (dexamethasone intraocular suspension) for Treating Inflammation Associated With Cataract Surgery
Newark, CA (February 12, 2018) – Icon Bioscience, Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced that the United... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

Do Corticosteroids Improve Diabetic Macular Edema Outcomes? Do Corticosteroids Improve Diabetic Macular Edema Outcomes?
Drs Matt Starr and Sophie Bakri on a randomized trial studying the value of adding intravitreal dexamethasone to anti-VEGF therapy.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2018 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS ® (carfilzomib) Label
Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial THOUSAND OAKS, Calif., Jan. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include updated overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in patients with relapsed or refractory multiple myeloma (KYPROLIS and dexamethasone [Kd] versus Velcade® [bortezomib] and dexamethasone [Vd]). The ENDEAVOR trial ...
Source: Amgen News Release - January 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Addition Of Overall Survival Data To KYPROLIS ® (carfilzomib) Label
Phase 3 Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Velcade® (Bortezomib) and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Overall Survival Results Support Use of KYPROLIS in Combination With Dexamethasone as New Standard of Care THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS&re...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Overall Survival Analysis From KYPROLIS ® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Results Support Early Use of KYPROLIS at First Relapse THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that the addition of KYPROLIS® (carfilzomib) to lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent ver...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Comparison of Effect of Oral Premedication with Ibuprofen or Dexamethasone on Anesthetic Efficacy of Inferior Alveolar Nerve Block in Patients with Irreversible Pulpitis: A Prospective, Randomized, Controlled, Double-blind Study.
Bull Tokyo Dent Coll. 2017;58(4):231-236. doi: 10.2209/tdcpublication.2016-0050.AbstractThe purpose of this prospective, randomized, double-blind, placebo-controlled study was to determine the effect of preoperative oral administration of ibuprofen or dexamethasone on the success rate of inferior alveolar nerve block (IANB) in patients with symptomatic irreversible pulpitis. Seventy-eight patients with irreversible pulpitis were randomly divided into 3 groups (26 per group) and given one of the following at 1 hr prior to performing local anesthesia: a placebo; 400 mg ibuprofen; or 4 mg dexamethasone. Each patient recorded ...
Source: Dental Technology Blog - December 28, 2017 Category: Dentistry Source Type: news

Rolapitant-Based Antiemetic Combination Improves CINV Symptoms
Rolapitant plus 5-HT3 receptor antagonist and dexamethasone is well tolerated and more effectively controls chemotherapy-induced nausea and vomiting compared with 5-HT3 and dexamethasone alone. (Source: CancerNetwork)
Source: CancerNetwork - December 14, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Nausea and Vomiting News Source Type: news

pSivida touts pilot osteoarthritis trial for Durasert implant
pSivida (NSDQ:PSDV) touted results today from a Phase I safety and efficacy pilot trial of its sustained-release Durasert implant in patients with osteoarthritis of the knee. The company’s Durasert tech, combined with an implantable device from the Hospital for Special Surgery, was designed to continuously deliver a low dose of dexamethasone into the knee joint. Six patients with osteoarthritis of the knee were followed throughout the study for six months. Get the full story at our sister site, Drug Delivery Business News. The post pSivida touts pilot osteoarthritis trial for Durasert implant appeared first...
Source: Mass Device - December 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Implants Orthopedics Pharmaceuticals Wall Street Beat pSivida Corp. Source Type: news

Combo Antiemetic Therapy Safe, Effective for Testicular Cancer Patients on Cisplatin Chemotherapy
Researchers found that combining palonosetron, aprepitant, and dexamethasone represents an effective and well-tolerated treatment to prevent CINV in testicular cancer patients receiving cisplatin. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Genitourinary Cancers Nausea and Vomiting News Testicular Cancer Source Type: news

KYPROLIS ® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Results Highlighted During Oral Presentation at ASH 2017 Addition of KYPROLIS to Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone Regulatory Applications Submitted in the U.S. to add ASPIRE Overall Survival Results to KYPROLIS Label THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS, demonstrating that the addition of KYPROLIS® (carfilzomib)...
Source: Amgen News Release - December 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

PharmaMar presents positive results of the pivotal Phase III trial with plitidepsin in MM
(Pharmamar) As previously informed, the Phase III trial, ADMYRE, which compared plitidepsin in combination with dexamethasone versus dexamethasone alone met its primary endpoint, progression free survival, and secondary objectives, overall survival and safety (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news

Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema
Adding dexamethasone to continued ranibizumab treatment reduces retinal thickness but does not improve vision in patients with persistent diabetic macular edema (DME), according to results from a phase 2 randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

iVeena finishes pilot trial of sustained-release implant
iVeena Delivery Systems said earlier this month that it finished a pilot trial for its IVMED-10 bioerodible implant designed to treat pain and inflammation after cataract surgery. Placed during cataract surgery, the sustained-release implant delivers dexamethasone for two weeks from the lens capsule. Get the full story at our sister site, Drug Delivery Business News. The post iVeena finishes pilot trial of sustained-release implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pain Management Pharmaceuticals Surgical iveenadeliverysystems Source Type: news

Maxidex Ointment (Dexamethasone Sodium Phosphate Ophthalmic) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 15, 2017 Category: Drugs & Pharmacology Source Type: news

Maxidex Suspension (Dexamethasone Ophthalmic Suspension) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 15, 2017 Category: Drugs & Pharmacology Source Type: news